Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
äŒæ¥ã³ãŒãRGNT
äŒç€ŸåRegentis Biomaterials Ltd
äžå Žæ¥Dec 04, 2025
æé«çµå¶è²¬ä»»è
ãCEOãHazum (Eli)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°60, Medinat Hyahudim
éœåžHERZLIYA
蚌åžååŒæNASDAQ OMX â NASDAQ Basic Amex
åœIsrael
éµäŸ¿çªå·4676652
é»è©±çªå·97246265502
ãŠã§ããµã€ãhttps://www.regentis.co.il/
äŒæ¥ã³ãŒãRGNT
äžå Žæ¥Dec 04, 2025
æé«çµå¶è²¬ä»»è
ãCEOãHazum (Eli)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã